KPL3,520.00

Kwality Pharmaceuticals Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersBPLPHARMAJENBURPHMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
View
In ₹ Crore except Per Share
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Revenue from Operations456.1251.0307.2
Total Income459.6
Expenses
+ Cost of Materials Consumed199.3113.2153.8
+ Purchases of Stock-in-Trade3.80.00.9
+ Changes in Inventories-2.5-3.2-1.5
+ Employee Benefit Expense20.129.932.5
+ Finance Costs2.96.010.4
+ Depreciation & Amortisation10.614.919.5
Total Expenses298.0211.6270.4
EBITDA171.760.366.6
EBIT161.145.447.1
Profit
Pretax Income161.725.831.5
+ Current Tax41.06.5
+ Deferred Tax0.30.1
Tax Expense41.3
Net Income120.0
+ Other Comprehensive Income-0.3
Per Share
Basic EPS115.7018.45
Diluted EPS115.7018.45
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit255.5140.9154.0
Gross Margin %56.0256.1550.13
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.